Dr. Rimel on the Importance of BRCA and HRD Testing in Ovarian Cancer


In Partnership With:

Bobbie J. Rimel, MD, discusses the importance of testing patients with ovarian cancer for homologous recombination deficiency (HRD) or homologous recombination proficiency (HRP), and BRCA mutation status.

Bobbie J. Rimel, MD, an assistant professor of obstetrics and gynecology at Cedars-Sinai Medical Center, discusses the importance of testing patients with ovarian cancer for homologous recombination deficiency (HRD) or homologous recombination proficiency (HRP), and BRCA mutation status.

It is important to test and identify patients with BRCA mutations in order to determine which type of therapy they are eligible for, as well as if cascade testing is needed, Rimel states. This offers patients’ family members the ability to also be tested for cancer screening prevention.

Additionally, HRD testing is valuable for understanding a patient's magnitude of benefit with maintenance PARP inhibitors, Rimel continues. Patients who are HRD have different projected progression-free survival outcomes than those who are HRP, Rimel adds. Accordingly, knowing their HRD status can better inform and guide patients' treatment decisions, Rimel concludes.

Related Videos
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH
Neil D. Gross, MD, FACS
Dae Won Kim, MD, Gastrointestinal Oncology Program, Moffitt Cancer Center